Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

Bibliographic Details
Main Authors:	Zhao, Xinmin, Xu, Xiaofeng, Zhang, Qunling, Jia, Zhen, Sun, Si, Zhang, Jian, Wang, Biyun, Wang, Zhonghua, Hu, Xichun
Format:	Online
Language:	English
Published:	BioMed Central 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3196722/

Similar Items

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
by: Wang, Leiping, et al.
Published: (2011)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer
by: Zhao, Xinmin, et al.
Published: (2015)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
by: LI, FENQIANG, et al.
Published: (2014)

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
by: Alcaraz, A, et al.
Published: (2013)

Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole
by: Sun, Shengliang, et al.
Published: (2016)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
by: Pietrantonio, Filippo, et al.
Published: (2016)

Differential effect of zoledronic acid on normal trabecular and cortical bone density in oncologic patients with bone metastases
by: Quattrocchi, Carlo C., et al.
Published: (2012)

The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
by: Hadji, Peyman, et al.
Published: (2012)

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
by: Jia Jin, et al.
Published: (2018-04-01)

Biochemical prediction of response of bone metastases to treatment.
by: Coleman, R. E., et al.
Published: (1988)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
by: Sun, Si, et al.
Published: (2014)

Metronomic chemotherapy
by: Maiti, Rituparna
Published: (2014)

RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study
by: Mercatali, Laura, et al.
Published: (2013)

Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases
by: GUI, QI, et al.
Published: (2015)

Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
by: Kapoor, Anoop, et al.
Published: (2011)

Controlled Delivery of Zoledronate Improved Bone Formation Locally In Vivo
by: Gou, Wenlong, et al.
Published: (2014)

Metronomics for thymic carcinoma
by: del Toro, Jacobo Muñoz, et al.
Published: (2014)

Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane
by: Lv, Fangfang, et al.
Published: (2015)

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model
by: Previdi, Sara, et al.
Published: (2013)

Head and neck cancer: metronomic chemotherapy
by: De Felice, Francesca, et al.
Published: (2015)

Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma after liver transplantation
by: He, Jian, et al.
Published: (2011)

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L
by: Liu, Rujiao, et al.
Published: (2016)

Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials
by: Coleman, Robert E., et al.
Published: (2013)

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial
by: Li, Ting, et al.
Published: (2015)

Bone structure and remodelling in stroke patients: Early effects of zoledronate☆
by: Poole, Kenneth E.S., et al.
Published: (2009)

Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid
by: Aft, Rebecca
Published: (2012)

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
by: Hadji, P., et al.
Published: (2012)

Guided bone regeneration with local zoledronic acid and titanium barrier: An experimental study
by: Dundar, Serkan, et al.
Published: (2016)

Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis
by: Fidan, Evren, et al.
Published: (2012)

Significant pain relief with loading dose zoledronic acid in bone metastases is only seen in patients with elevated initial serum C telopeptide (CTX)
by: Dekoninck, J, et al.
Published: (2011)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
by: Zhang, Jian, et al.
Published: (2015)

Thyroid Carcinoma with Bone Metastases: A Prognostic Factor Study
by: Wu, Karl, et al.
Published: (2008)

Experimental Study of the Triplet Synchronization of Coupled Nonidentical Mechanical Metronomes
by: Jia, Ji, et al.
Published: (2015)

Rhythmic synchronization tapping to an audio–visual metronome in budgerigars
by: Hasegawa, Ai, et al.
Published: (2011)

Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch
by: Malik, Prabhat Singh, et al.
Published: (2014)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
by: Agrawal, Archi, et al.
Published: (2014)

Metronomic palliative chemotherapy in maxillary sinus tumor
by: Patil, Vijay M., et al.
Published: (2016)

Metronomic chemotherapy for triple negative breast cancer?
by: Di Desidero, Teresa, et al.
Published: (2016)

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
by: Berruti, A., et al.
Published: (1996)

Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients
by: Li, Wenhua, et al.
Published: (2012)